Abstract Novel treatments are disclosed for increasing circulating coronary blood flow. These treatments are useful for individuals who are expected to otherwise exhibit symptoms of reduced coronary circulation. Such individuals include those having coronary artery disease, angina, particularly unstable angina and Prinzmetal's angina, and coronary vasospasm. In accordance with the disclosed methods, coronary vasodilation is accomplished through the administration of effective amounts of ibuprofen and/or flurbiprofen. At the indicated dosages, thromboxane synthesis is effectively inhibited without inhibiting prostacyclin synthesis. Flurbiprofen administration additionally results in thromboxane antagonism.
Inventors
👤 Allan M. Lefer
Bibliographic Details
Application Number—
JurisdictionUS
Data Sourcegoogle_patents
Last Synchronized2026-10-25 20:05
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
53 words
A method of treating a patient suffering from angina, coronary heart disease, or coronary vasospasm, and who exhibits periodic symptoms of reduced coronary blood flow, which comprises administering to said patient an amount of flurbiprofen effective to cause dilation of the coronary arteries of said patient, whereby coronary blood flow is substantially increased.
Claim 2
Independent Claim
53 words
A method of treating a patient suffering from angina, coronary heart disease, or coronary vasospasm, and who exhibits periodic symptoms of reduced coronary blood flow, which comprises administering to said patient an amount of flurbiprofen effective to cause dilation of the coronary arteries of said patient, whereby coronary blood flow is substantially increased.
Claim 3
Dependent Claim
31 words
The method of claim 1, wherein said administration comprises the step of orally administering from 0.75 to 6 mg/kg of body weight of flurbiprofen prior to the onset of said symptoms.
Claim 4
Dependent Claim
30 words
The method of claim 2, wherein said step of administration further comprises orally administering flurbiprofen in the amount of 1-3 mg of flurbiprofen per kilogram of said patient's body weight.
Claim 5
Dependent Claim
38 words
The method of claim 1, wherein said step of administering flurbiprofen comprises the step of introducing said flurbiprofen into said patient's bloodstream to achieve circulating coronary artery blood plasma levels of flurbiprofen from 10 ug/ml to 100 ug/ml.
Claim 6
Dependent Claim
25 words
The method of claim 4, wherein said step of administering further comprises achieving circulating coronary artery blood plasma levels of flurbiprofen of from 17-50 ug/ml.